Note: Single-source report; awaiting corroboration.
Alzheimer’s disease involves the accumulation of tau and amyloid-beta proteins in the brain, impairing thinking, memory, and daily function. Researchers are exploring early detection methods to improve treatment outcomes.
An NIH-funded study analyzed blood samples from 1,350 individuals in their 50s and 60s without Alzheimer’s diagnoses. The study measured Alzheimer’s-related protein forms and assessed participants’ cognitive abilities, comparing them to tests taken five years earlier.
Findings indicated that participants with higher levels of these proteins in their blood experienced greater declines in thinking speed and memory over five years. This suggests that disease processes may begin years before symptoms appear.
Dr. Kristine Yaffe from the University of California, San Francisco, noted that early detection could help patients modify risk factors and maintain mental sharpness. Further studies are needed to validate blood tests for clinical use.